| Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy K Patterson, V Prabhu, R Xu, H Li, Y Meng, N Zarabi, Y Zhong, R Batteson, ... European Urology Oncology 2 (5), 565-571, 2019 | 22 | 2019 |
| The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States RL Slater, Y Lai, Y Zhong, H Li, Y Meng, BH Moreno, JL Godwin, T Frenkl, ... Journal of Medical Economics 23 (9), 967-977, 2020 | 16 | 2020 |
| Modelling survival of patients treated with adjuvant nivolumab who have melanoma with lymph node involvement or metastatic disease after complete resection R Batteson, R Hart, M Hemstock, K Gooden, S Kotapati, S Roze, D Lee, ... PharmacoEconomics-open 4, 343-351, 2020 | 7 | 2020 |
| Modeling cancer treatments in the adjuvant setting: a targeted literature review of technology appraisals of adjuvant therapies submitted to the National Institute for Health … R Batteson, M Hemstock, R Hart, O Saunders, S Kotapati, K Gooden, ... Barcelona: ISPOR Europe, 2018 | 2 | 2018 |
| Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping M Yang, H Vioix, ES Hook, AJ Hatswell, RL Batteson, BR Gaumond, ... Value in Health 26 (8), 1155-1163, 2023 | 1 | 2023 |
| CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) A Hatswell, R Batteson, E Hook, H Wheat, H Vioix, T McLean, ... Value in Health 25 (12), S21-S22, 2022 | 1 | 2022 |
| CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14 … H Vioix, A Hatswell, T McLean, C Day, R Batteson, E Hook, S Alexopoulos, ... Value in Health 25 (12), S36, 2022 | 1 | 2022 |
| RWD51 Demonstrating Internal and External Validity in Real-World Datasets: A Case Study in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) R Batteson, E Hook, H Vioix, A Hatswell Value in Health 25 (12), S458, 2022 | 1 | 2022 |
| PCN226 THE COST-EFFECTIVENESS AND RELAPSE-REDUCTION BENEFIT OF INTRODUCING ADJUVANT NIVOLUMAB FOR PATIENTS WITH COMPLETELY WITH RESECTED MELANOMA WITH LYMPH NODE INVOLVEMENT OR … D Ntais, R Batteson, R Hart, M Hemstock, D Lee Value in Health 22, S480, 2019 | 1 | 2019 |
| PRM21 Modeling Survival of Patients With Completely Resected Advanced Melanoma After Adjuvant Treatment With Nivolumab Versus Observation or Interferon R Batteson, M Hemstock, R Hart, S Kotapati, K Gooden, A Amadi, D Lee ISPOR Europe, 2018 | 1 | 2018 |
| Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring MET ex14 Skipping … R Batteson, E Hook, H Wheat, AJ Hatswell, H Vioix, T McLean, ... Targeted Oncology, 1-11, 2024 | | 2024 |
| HTA234 How Long Is the Weight? A Framework for Linear Interpolation of the National Institute for Health and Care Excellence (NICE) Severity Weighting in the Context of … S Critchlow, T Douglas, R Batteson, K Patel, S McLachlan, F Mughal Value in Health 26 (12), S365, 2023 | | 2023 |
| EE372 Modeling the Cost-Effectiveness in a Sub-Population: Tepotinib Versus Chemoimmunotherapy (C+ IO) in Untreated Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring … R Batteson, H Vioix, H Wheat, W Battershill Value in Health 26 (12), S122, 2023 | | 2023 |
| HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals R Batteson, S Critchlow, T Douglas, K Patel, S McLachlan, F Mughal Value in Health 26 (12), S378, 2023 | | 2023 |
| CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14 … E Hook, R Batteson, P Christopoulos, F Guisier, S Ekman, A Hatswell, ... Value in Health 26 (12), S44, 2023 | | 2023 |
| EE146 Cost-effectiveness of Tepotinib for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring Metex14 Skipping Alterations in Spain E Arriola, R Batteson, E Hook, H Wheat, H Vioix, M Morros, M Águila, ... Value in Health 26 (6), S86, 2023 | | 2023 |
| PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC … E Hook, H Vioix, R Batteson, T McLean, A Hatswell Value in Health 25 (12), S420, 2022 | | 2022 |
| EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping T McLean, S Alexopoulos, E Hook, R Batteson, H Vioix Value in Health 25 (12), S143, 2022 | | 2022 |
| Modelling survival for adjuvant nivolumab in stage III/IV melanoma R Batteson PharmacoEconomics & Outcomes News 839, 28-19, 2019 | | 2019 |
| Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States. Y Zhong, Y Lai, H Li, R Batteson, Y Meng, TL Frenkl, JL Godwin, ... Journal of Clinical Oncology 37 (15_suppl), e16010-e16010, 2019 | | 2019 |
